| 1. | | No longer recruiting | A 12-week, multicenter, safety and dose-ranging study of 3 oral doses of TCH346 in patients with Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis |
| 2. | | Recruiting | Bisphosphonate Treatment of Osteogenesis Imperfecta
Condition: Osteogenesis Imperfecta |
| 3. | | No longer recruiting | The Effect of Zometa on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
Condition: Prostate Cancer |
| 4. | | No longer recruiting | The efficacy and safety of omalizumab in patients with severe persistent asthma
Condition: Asthma |
| 5. | | Recruiting | The Efficacy and Safety of Xolair in Children (6 - <12 years) with Moderate-Severe, Inadequately Controlled Allergic Asthma
Condition: Asthma |
| 6. | | Suspended | EPO906 in Carcinoid and other Neuroendocrine Tumors
Conditions: Carcinoid; Neuroendocrine Tumors |
| 7. | | Recruiting | EPO906 in Patients with Late Stage Non-Small-Cell Lung Cancer (NSCLC)
Conditions: Non-small cell lung cancer; NSCLC |
| 8. | | Suspended | EPO906 Therapy in Patients with Advanced Breast Cancer
Condition: Breast Neoplasms |
| 9. | | Completed | EPO906 Therapy in Patients with Advanced Colorectal Cancer
Conditions: Colorectal Neoplasms; Colonic Neoplasms |
| 10. | | Suspended | EPO906 Therapy in Patients with Advanced Kidney Cancer
Condition: Kidney Neoplasms |
| 11. | | Completed | EPO906 Therapy in Patients with Advanced Melanoma
Condition: Melanoma |
| 12. | | Completed | EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
| 13. | | Suspended | EPO906 Therapy in Patients with Prostate Cancer
Condition: Prostatic Neoplasms |
| 14. | | No longer recruiting | First-line treatment of metastatic colorectal cancer with oxaliplatin/5-FU/leucovorin plus PTK787/ZK 222584 or placebo
Conditions: Colorectal Neoplasms; Colonic Neoplasms; Rectal Neoplasms |
| 15. | | Recruiting | Gleevec Trial in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia |
| 16. | | No longer recruiting | HORIZON-PFT: Pivotal Fracture Trial
Condition: Osteoporosis |
| 17. | | Completed | Investigation into Delay to Diagnosis of Alzheimer's Disease with Exelon (InDDEx)
Conditions: Alzheimer Disease; Cognition Disorders |
| 18. | | Completed | Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer |
| 19. | | Recruiting | New bisphosphonate treatment for Paget's disease
Condition: Paget's Disease of Bone |
| 20. | | Recruiting | New bisphosphonate treatment for Paget's disease
Condition: Paget's Disease of Bone |
| 21. | | Recruiting | Non-small Cell Lung Cancer Study US75 (Z-PACT)
Condition: Non Small Cell Lung Carcinoma |
| 22. | | No longer recruiting | Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Conditions: recurrent colon cancer; Diarrhea; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer |
| 23. | | No longer recruiting | Open-label Trial on the Effect of I.V. Zometa 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis
Condition: Prostate Cancer |
| 24. | | Recruiting | Osteoarthritis Initiative (OAI): A Knee Health Study
Conditions: Osteoarthritis; Knee Osteoarthritis |
| 25. | | Completed | Pediatric Epilepsy Study
Conditions: Epilepsy; Epilepsies, Partial |
| 26. | | Completed | Pediatric Epilepsy Study
Condition: Epilepsy |
| 27. | | Recruiting | Pediatric Hypothalamic Obesity
Condition: Obesity |
| 28. | | Recruiting | PKC412 in Patients with Acute Myeloid Leukemia and Patients with Myelodysplastic Syndrome with either Wild Type or Mutated FLT3
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes |
| 29. | | Recruiting | A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
Condition: Prostate Cancer |
| 30. | | Recruiting | PTK 787 and Gleevec in Patients with AML, AMM, and CML-BP
Conditions: Acute Myelogenous Leukemia; Agnogenic Myeloid Metaplasia; Chronic Myelogenous Leukemia |
| 31. | | Recruiting | RAD001 in Recurrent Endometrial Cancer
Condition: Endometrial Cancer |
| 32. | | Recruiting | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
Conditions: Leukemia; Mantle Cell Lymphoma; Myelofibrosis |
| 33. | | No longer recruiting | Safety & Efficacy of ICL670 vs. deferoxamine in Beta-thalassemia patients with iron overload due to blood transfusions
Condition: beta-Thalassemia |
| 34. | | Completed | Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
Conditions: Candidiasis, Oral; HIV Infections |
| 35. | | No longer recruiting | Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients with Iron Overload due to Blood Transfusions
Condition: Anemia, Sickle Cell |
| 36. | | Completed | Sandostatin LAR® Depot in Patients with Primary Insulin Hypersecretion (PIH) and at least Moderate Obesity
Conditions: Primary Insulin Hypersecretion; Obesity |
| 37. | | No longer recruiting | STI571 Compared With Interferon alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Conditions: Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; Quality of Life |
| 38. | | No longer recruiting | STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
Conditions: accelerated phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia; ... |
| 39. | | No longer recruiting | STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
Conditions: Philadelphia chromosome positive chronic myelogenous leukemia; Philadelphia chromosome negative chronic myelogenous leukemia; ... |
| 40. | | Completed | STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon alfa
Conditions: Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; ... |
| 41. | | No longer recruiting | STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Conditions: Neoplasms; Diarrhea |
| 42. | | Recruiting | Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
Condition: Acromegaly |
| 43. | | No longer recruiting | Study evaluating 4 oral doses of TCH346 and placebo administered once daily in patients with Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis |
| 44. | | Recruiting | Study Evaluating SOM230 in Patients with Metastatic Carcinoid Tumors
Condition: Carcinoid Tumors |
| 45. | | No longer recruiting | Study of ICL670 in iron overload from beta-thalassemia unable to be treated with deferoxamine or chronic anemias
Conditions: beta-Thalassemia; Myelodysplastic Syndromes; Fanconi Syndrome; Anemia, Diamond-Blackfan; Anemia, Aplastic |
| 46. | | Recruiting | A Study to Assess SOM230 in Patients with Pituitary Cushing’s Disease
Condition: Cushing's Syndrome |
| 47. | | Recruiting | To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture.
Conditions: Osteoporosis; Hip Fracture |
| 48. | | Recruiting | Treatment of Paget's Disease using Risedronate as a Comparator
Condition: Paget's Disease of Bone |
| 49. | | No longer recruiting | Treatment of Patients with Previously Treated Metastatic Colorectal Cancer with Oxaliplatin/5FU/LV and PTK787 or Placebo
Conditions: Colorectal Neoplasms; Colonic Neoplasms; Rectal Neoplasms |
| 50. | | Recruiting | Treatment of von Hippel-Lindau (VHL)-Related Hemangioblastoma with PTK787/ZK 222584
Conditions: von Hippel-Lindau Disease; CNS hemangioblastoma; Retinal Hemangioblastoma |
